Amgen Inc (AMGN) Stock AnalysisAMGNAmgen Inc

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Amgen Inc is a good buy right now, with a current price of $439.26 and a forward P/E ratio of 16.67, indicating potential for future earnings growth. The company has demonstrated strong financial performance, achieving a 10% year-over-year revenue growth to approximately $36.7 billion and a net income of about $7.7 billion, reflecting a net margin of 21%. However, investors should be cautious of pricing pressures from government and commercial payers, which pose a risk to profitability.

25 analysts cover AMGN: 10 rate it Buy, 15 Hold and 0 Sell. The average price target is 363.10.